Alzheimer's Disease Clinical Trials in Phoenix

Showing 21-40 of 107 trials

Anti-viral Therapy in Alzheimer's Disease

NCT03282916

Anti-viral therapy in Alzheimer's disease will investigate the efficacy of treating patients with mild Alzheimer's disease with the U.S.A marketed generic anti-viral drug Valtrex (valacyclovir, 500mg oral tablet). Valacyclovir, titrated to 4 grams per day, repurposed to treat Alzheimer's disease, will be compared to matching placebo in the treatment of 130 mild AD patients (65 valacyclovir, 65 placebo) who test positive for herpes simplex virus-1 (HSV1) or herpes simplex virus-2 (HSV2). The study will be a randomized, double-blind, 18-month Phase II proof of concept trial.

Alzheimer DiseaseHerpes Simplex 1Herpes Simplex 2

Columbia University120 participantsStarted Feb 2018

Phoenix, Arizona, United States • New York, New York, United States • New York, New York, United States

COMPLETEDPHASE2< 1 mile

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Mild to Moderate Alzheimer's Disease

Cognition Therapeutics153 participantsStarted Oct 2018

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Stamford, Connecticut, United States +29 more locations

Anti-viral Therapy in Alzheimer's Disease

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Alzheimer's Disease Trials in Other Cities

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

TRC-PAD Program: In-Clinic Trial-Ready Cohort

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Advancing Understanding of Transportation Options

Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium

Clinical Procedures to Support Research in ALS

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Other Conditions in Phoenix